Skip to main content
. 2020 Mar 30;9(4):830. doi: 10.3390/cells9040830

Figure 1.

Figure 1

The combination of PI3K-MAPK-mTOR inhibitors in thyroid cancer in preclinical studies. This figure resumes all combinatorial therapies including PI3K-MAPK-mTOR inhibitors in thyroid cancer. Each molecule represented with a specific color legend is associated with the molecules having the same color legend.